There are currently 1329 clinical trials in Atlanta, Georgia looking for participants to engage in research studies. Trials are conducted at various facilities, including Emory University, Emory University Hospital, Emory University Hospital/Winship Cancer Institute and Children's Health Care of Atlanta. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL
NCT03666000
Recruiting
This is a Phase 1/1b, nonrandomized, open-label, parallel assignment, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of azer-cel, an allogeneic anti-CD19 CAR T, in adults with r/r B ALL and r/r B-cell NHL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Winship Cancer Institute Emory University, Atlanta, Georgia +1 locations
Conditions: Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
Register for Updates
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
NCT05834478
Recruiting
This study is being done to answer the question: what is the effect of Vagal Nerve Stimulation (VNS) dosing on opioid withdrawal responses in individuals with a history of Opioid Use Disorders (OUDs)? Eligible participants will be in the study for one week in an inpatient research hospital stay, have an MRI scan, and have a follow-up call 1-3 months after their inpatient stay. Participants will complete several psychiatric questionnaires/interviews, physiological monitoring with several devices,... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/06/2025
Locations: Emory University Clinical Research Network, Atlanta, Georgia +5 locations
Conditions: Withdrawal Symptoms, Opioid Use Disorder, Opioid Use
Register for Updates
Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry
NCT05999084
Recruiting
The purpose of this registry is to compile information on patients who are receiving FDA-approved anti-amyloid mAbs in the course of their clinic visits in the Emory Cognitive Neurology Clinic and in Georgia Memory Net Memory Assessment Clinics.
Gender:
ALL
Ages:
Between 50 years and 90 years
Trial Updated:
03/06/2025
Locations: Georgia Memory Net Memory Assessment Clinic - Atlanta, Atlanta, Georgia +1 locations
Conditions: Alzheimer Disease
Register for Updates
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
NCT06024746
Recruiting
Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: CON-10022 Atlanta, GA Investigational Site, Atlanta, Georgia
Conditions: Heart Failure
Register for Updates
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
NCT06059391
Recruiting
This phase II clinical trial tests how well the cytomegalovirus-modified vaccinica Ankara (CMV-MVA) Triplex vaccine given to human leukocyte antigens (HLA) matched related stem cell donors works to prevent cytomegalovirus (CMV) infection in patients undergoing hematopoietic stem cell transplant. The CMV-MVA Triplex vaccine works by causing an immune response in the donors body to the CMV virus, creating immunity to it. The donor then passes that immunity on to the patient upon receiving the stem... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/06/2025
Locations: Northside Hospital, Atlanta, Georgia
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Register for Updates
IMPACT: Improving Maternal Postpartum Access to Care Through Telemedicine
NCT06218355
Recruiting
The purpose of this study is to compare two complex, multi-component evidence-based postpartum interventions in underserved populations of lower socioeconomic status in an effort to reduce maternal morbidity and mortality.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: Emory University School of Medicine, Atlanta, Georgia
Conditions: Postpartum Complication
Register for Updates
Cortical Electrophysiology of Response Inhibition in Parkinson's Disease
NCT06234995
Recruiting
Patients with Parkinson's Disease will be studied before, during, and after a deep brain stimulation implantation procedure to see if the stimulation location and the size of the electrical field produced by subthalamic nucleus (STN) DBS determine the degree to which DBS engages circuits that involve prefrontal cortex executive functions, and therefore have a direct impact on the patient's ability to inhibit actions.
Gender:
ALL
Ages:
Between 45 years and 75 years
Trial Updated:
03/06/2025
Locations: Emory University Hospital, Atlanta, Georgia +1 locations
Conditions: Parkinson Disease
Register for Updates
Cabozantinib in Combination with Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
NCT04878029
Recruiting
This phase I/Ib trial seeks to find out the best dose, possible benefits and/or side effects of cabozantinib in combination with enfortumab vedotin in treating urothelial cancer that has spread to nearby tissues and lymph nodes (locally advanced) or other parts of the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to a toxic agent called vedotin. Enfortumab... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2025
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Unresectable Urothelial Carcinoma
Register for Updates
Neurovascular Transduction During Exercise in Chronic Kidney Disease
NCT02947750
Recruiting
The purpose of this study is to find out why patients with chronic kidney disease (CKD) have poor exercise capacity and to explore what causes an increase in blood pressure during exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate). This study will also test whether or not regular exercise on a bicycle and/or treatment with 6R-BH4 (Kuvan) pills, or histidine and beta-alanine supplementation improves these measures during exercise. 6R-BH4 is currently FDA-... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/03/2025
Locations: Emory University Hospital Midtown, Atlanta, Georgia +1 locations
Conditions: Renal Insufficiency, Chronic
Register for Updates
Mindfulness in Chronic Kidney Disease
NCT04099992
Recruiting
This study will test whether mindfulness meditation (MM) improves sympathetic function in chronic kidney disease (CKD) and whether transcutaneous vagus nerve stimulation (tVNS) optimizes the sympatho-inhibitory effects of mindfulness meditation (MM) and restores autonomic balance in CKD patients.
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
03/03/2025
Locations: Atlanta VA Medical Center, Atlanta, Georgia
Conditions: Chronic Kidney Diseases
Register for Updates
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT05785741
Recruiting
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Research Site 111, Atlanta, Georgia
Conditions: Advanced Solid Tumor
Register for Updates
Response to Emerging Antimicrobial Resistance With Containment Microbiota Therapy (REACT)
NCT06321536
Recruiting
REACT is a phase two, open-label, randomized, controlled trial of microbiota therapy (MT) to reduce colonization with multi-drug resistant organisms (MDRO). REACT is designed to assess the safety and efficacy of MT administered to subjects colonized with a MDRO. The overarching hypothesis is that MT can reduce MDRO colonization with safety that is comparable to observation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Emory University Hospital, Atlanta, Georgia
Conditions: Multi-Drug Resistant Organism Colonization
Register for Updates